- Home
- SGD vs SBFM Comparison
SGD vs SBFM Comparison
Compare SGD & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGD | SBFM |
|---|---|---|
| Founded | 2021 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 7.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SGD | SBFM |
|---|---|---|
| Price | $0.33 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 2.2M | 49.8K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,970,752.00 | ★ $37,323,742.00 |
| Revenue This Year | N/A | $10.26 |
| Revenue Next Year | N/A | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2770.15 | 13.24 |
| 52 Week Low | $0.17 | $1.17 |
| 52 Week High | $3.03 | $3.90 |
Technical Indicators
Market Signals| Indicator | SGD | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 29.48 | 37.32 |
| Support Level | $0.17 | $1.32 |
| Resistance Level | $0.30 | $1.48 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 11.37 | 16.67 |
Price Performance
Historical ComparisonAbout SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.